Tilray Medical Study Finds Oral THC:CBD Extract Offers Faster, Higher Bioavailability

Tilray Brands Inc. (NASDAQ:TLRY) is one of the best penny stocks under $1 to buy now. On June 26, Tilray Brands, through its medical division, Tilray Medical, published a new scientific study on the bioavailability of different cannabinoid formulations.

This research, conducted on healthy volunteers, compared Tilray’s oral THC:CBD extract with oromucosally administered nabiximols.

Tilray Medical Study Finds Oral THC:CBD Extract Offers Faster, Higher Bioavailability

A busy pharmaceutical lab with technicians developing hemp-derived CBD products.

The findings show that Tilray’s oral extract resulted in higher and faster concentrations of THC and CBD in the bloodstream.

Tilray Brands Inc. (NASDAQ:TLRY) is a lifestyle consumer products company that researches, cultivates, processes, and distributes medical cannabis products in Canada, the US, Europe, Australia, New Zealand, Latin America, and internationally.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.